Soliris® (eculizumab) – New indication
June 27, 2019 - The FDA announced the approval of Alexion Pharmaceuticals’ Soliris (eculizumab), for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Download PDF
